Orthofix Medical/$OFIX
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Orthofix Medical
Orthofix Medical Inc. is a medical device company delivering orthopedic and spine solutions to healthcare providers. The company has two reportable segments: Global Spine and Global Limb Reconstruction. The Global Spine segment offers bone growth therapies, spinal implants, biologics, and enabling technologies used in spinal procedures. The Global Limb Reconstruction segment provides products and solutions for limb deformity correction, limb lengthening, fracture management, and limb preservation, supported by digital technologies. It generates the majority of its revenue from the Global Spine segment.
- Ticker
- $OFIX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 1,605
- Headquarters
- Lewisville, United States
- Website
- orthofix.com
Orthofix Medical Metrics
BasicAdvanced
$382M
-
-$1.53
0.67
-
Price and volume
Market cap
$382M
Beta
0.67
52-week high
$16.99
52-week low
$8.50
Average daily volume
409K
Financial strength
Current ratio
2.841
Quick ratio
1.526
Long term debt to equity
0.603
Total debt to equity
0.61
Interest coverage (TTM)
-1.81%
Profitability
EBITDA (TTM)
20.928
Gross margin (TTM)
71.26%
Net profit margin (TTM)
-7.41%
Operating margin (TTM)
-4.51%
Effective tax rate (TTM)
-2.39%
Revenue per employee (TTM)
$520,000
Management effectiveness
Return on assets (TTM)
-2.75%
Return on equity (TTM)
-13.91%
Valuation
Price to revenue (TTM)
0.453
Price to book
0.89
Price to tangible book (TTM)
2.27
Price to free cash flow (TTM)
-13.58
Free cash flow yield (TTM)
-7.36%
Free cash flow per share (TTM)
-0.691
Growth
Revenue change (TTM)
2.99%
Earnings per share change (TTM)
-51.82%
3-year revenue growth (CAGR)
11.66%
10-year revenue growth (CAGR)
7.39%
3-year earnings per share growth (CAGR)
-28.49%
10-year earnings per share growth (CAGR)
33.31%
What the Analysts think about Orthofix Medical
Analyst ratings (Buy, Hold, Sell) for Orthofix Medical stock.
Analyst projections of the future price of Orthofix Medical stock.
Bulls say / Bears say
Second-quarter sales rose 5% on a pro forma constant-currency basis, and Orthofix raised its 2026 sales and adjusted EBITDA forecasts. The higher outlook and expected margin expansion point to improving execution. (Orthofix Medical)
Global Limb Reconstruction sales grew 11% and Global Spine Fixation sales grew 10% in constant currency in the second quarter. Stronger demand in these businesses offers growth beyond the company’s struggling smaller US spine distributors. (The Motley Fool)
Medicare reimbursement for non-invasive bone growth stimulators returned to its prior level, removing a recent headwind for Orthofix’s Therapeutic Solutions business. This could support sales as the reimbursement change feeds through in the second half. (Orthofix Medical)
Smaller US spine distributors have been weaker than expected for several quarters, and management expects the challenges to persist through the rest of 2026. That channel weakness is limiting growth despite stronger performance from larger distributors. (The Motley Fool)
Orthofix reported a $15.8 million second-quarter net loss, while cash fell to $104.4 million and long-term debt stood at $221.6 million. The losses and debt burden leave less room for error if its operational recovery stalls. (Orthofix Medical, The Motley Fool)
A European distributor inventory arrangement is expected to add about $15 million to 2026 sales, but management expects it to create an approximately $22 million sales headwind in 2027. The arrangement also delays some cash receipts, adding near-term pressure on cash flow. (The Motley Fool)
Data summarised monthly by Lightyear AI. Last updated on 3 Oct 2026.
Orthofix Medical Financial Performance
Revenues and expenses
Orthofix Medical Earnings Performance
Company profitability
Upcoming events
No upcoming events
Orthofix Medical News
AllArticlesVideos
Funds containing Orthofix Medical
AllUSDEURGBP
Fund name | Fund size | $OFIX weighting |
|---|---|---|
iShares Ageing Population$AGED | $953M | 0.03% |
iShares Ageing Population€AGED | €822M | 0.03% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.02% |
SPDR Russell 2000 US Small Cap£R2SC | £4.1B | 0.02% |
Xtrackers S&P 500 Swap£XSPX | £3.1B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.